Home Press Press Releaeses

Press Releases

+++ 30 Years of IZB: An Anniversary Marked by Innovation +++
+++ Thermosome Initiates Final Dose Level in Phase I Trial of Lead compound THE001 +++
+++ SciRhom announces first dosing in First-in-Man trial for lead program SR-878 +++
+++ Eisbach receives IND clearance for lead candidate EIS-12656, a first-in-class allosteric inhibitor of ALC1, from the FDA +++
+++ Insempra completes $20 million financing to advance the development of next-generation bio-based ingredients. +++
+++ Tubulis presents novel preclinical data for its lead ADC candidates targeting solid tumors at AACR 2024 +++
+++ Eisbach receives USD 4.5 million investment from Cancer Focus Fund to support Phase 1/2 trial of lead candidate EIS-12656 +++
+++ Tubulis secures significant EUR 128 million Series B2 financing +++
+++ Novel small molecule drugs of the future targeting the CNS +++
+++ Christian Gnam succeeds Dr. Peter Zobel as new Managing Director of the Biotechnology Innovation and Start-up Center (IZB) +++
+++ Thermosome advances Phase I trial with lead candidate THE001 to next dose level +++
+++ MorphoSys enters into Business Combination Agreement to be Acquired by medicines company Novartis +++
+++ CatalYm strengthens Board of Directors and Scientific Advisory Board with key appointments +++
+++ Tubulis out-licenses IND-ready ADC for the treatment of lymphoma to Oncoteq +++
+++ MorphoSys ends the year with positive phase 3 data and successful cash capital increase of approximately EUR 102.7 million +++
+++ Oncology experts to support the development of Thermosome’s clinical candidate THE001 +++
+++ Renowned Peutinger-Collegium visits the IZB +++
+++ SciRhom submits clinical trial application for first-in-human trials with lead candidate SR-878 +++
+++ GoingPublic celebrates a quarter century of biotech +++
+++ 4SC’s resminostat receives Orphan Drug Designation from the European Medicines Agency +++
+++ Dr. Peter Hanns Zobel, CEO of IZB, Bids Farewell +++
+++ Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology +++
+++ High-Profile Clinical Advisory Board for Thermosome +++
+++ Successful Economic Reception at IZB with Dr. Theo Waigel, Former Federal Minister of Finance, as Guest Speaker +++
+++ MorphoSys’ program tulmimetostat receives FDA Fast Track designation +++
+++ adivo becomes part of the world’s leading animal health company Zoetis +++
+++ The Munich Bavaria Student Union visits the IZB +++
+++ Bind-X secures €10 million in financing as part of its Series B financing round +++
+++ Biotech Companies from Munich’s start-up center IZB convince prominent partners with excellent research +++
+++ 23 students from Europe visited the IZB as part of the AMGEN Scholar Program +++
+++ M1 – Munich Medical Alliance: Becoming Germany’s No. 1 medical hub +++
+++ Neutralizing GDF-15: Development of a new class of anti-cancer immunotherapy +++
+++ Vivoryon Therapeutics highlights progress of lead candidate varoglutamstat in Alzheimer’s disease +++
+++ leon-nanodrugs welcomes Dr. Hans Frickel as new CEO +++
+++ Pioneering research projects at the 8th Life Science Pitch Day at the IZB +++
+++ Japanese delegation visits the IZB +++
+++ Bavarian biotechnology maintains its position in the crisis and continues to grow +++
+++ Biotech company Origenis welcomes Prof. Hendrik Liebers as Chairman of the Board +++
+++ Official handover ceremony at the Annual Meeting of the Max Planck Society +++
+++ Secarna appoints new Chief Business Officer +++
+++ Bicoll showcases at BIO International Convention +++
+++ Thermosome joins IMAGIO consortium to advance development of cancer therapies for soft tissue sarcoma +++
+++ Breakthrough in fluorescence microscopy at the Max Planck Institute of Biochemistry +++
+++ New preclinical data show long-term antitumor effects of Secarna Pharmaceuticals’ antisense oligonucleotide (ASO) therapies +++
+++ Biotech report by vfa: Biopharmaceuticals successfully gain market share +++
+++ Preclinical efficacy and safety data for ViGeneron’s innovative approach to the treatment of Retinitis Pigmentosa +++
+++ MPI of Biochemistry: Nature publication addressing the “dark matter” of proteomics +++
+++ Non-nutritive sweeteners may affect the human immune system +++
+++ LMU Hospital’s annual reception returned this year with exciting topics and a multimedia “magic show” +++
+++ Invitris receives 250,000 EUR to complete spin-out from TUM +++
+++ Eisbach starts phase I clinical trial with COVID-19 antiviral +++
+++ IZB Connects with Shanghai Zhangjiang Hi-Tech Park +++
+++ Specific packaging of DNA affects cell division +++
+++ Tubulis Enters Strategic Partnership with BMS +++
+++ Insempra launches its first functional component for consumer goods +++
+++ ERC Advanced Grant of nearly 2.1 million euros for Prof. Dr. Brenda Schulman +++
+++ Vivoryon Therapeutics gives update on clinical development of its lead candidate against Alzheimer’s Disease +++
+++ Secarna Pharmaceuticals and SciNeuro Pharmaceuticals form partnership +++
+++ adivo expands into new headquarters as first clinical study begins +++
+++ Thermosome’s Lead Program THE001 receives regulatory approval for first-in-human trial +++
+++ Construction of the “New Hauner” at the Grosshadern Campus has started +++
+++ Insempra names new Chief Operating Officer +++
+++ Training events for project managers and biological safety officers +++
+++ The zebrafish brain as a map +++
+++ MorphoSys stops proprietary pre-clinical research programs and further optimizes cost structure +++
+++ Innovation and Start-up Center Biotechnology (IZB) welcomes Invitris +++
+++ When life begins too early +++
+++ US-based Neuron23 starts Phase 1 clinical trial in Parkinson’s Disease +++
+++ Expansion of the Munich “science line” has started +++
+++ Enno Spillner to join Formycon as CFO +++

PDF archive

2013

Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim

Evotec enters integrated alliance with AstraZeneca in kidney disease

Evotec to hold R&D Day 2013

Evotec and Harvard University to collaborate on exploration of enteroendocrine signals affecting key metabolic pathways

Evotec receives clinical milestone as part of its discovery alliance with Boehringer Ingelheim

SuppreMol appoints industry expert Michael Tansey as Chief Development Officer

Evotec AG reports H1 2013 results

4SC reports second quarter 2013 financial results

4SC to host conference call on 8 August 2013 to present half year results 2013

4SC’s partner Yakult Honsha starts clinical Phase I/II study with cancer compound resminostat in non-small-cell lung cancer (NSCLC) in Japan

SuppreMol Raises € 9.5 million in Extended Series D Financing Round

Evotec and Harvard University to collaborate on development of new class of antibacterials

4SC significantly improves operating result in first quarter of 2013 and resolves to focus its development strategy

4SC to host conference call on 14 May 2013 to present first quarter results of 2013

Dana-Farber’s Belfer Institute for Applied Cancer Science and Evotec establish collaboration in oncology

ChromoTek wins INDUSTRY PRIZE 2013 for its pioneering Chromobody® technology for the real time analysis of cellular molecules in live cells

Forward step by step with Action Plan 2016 – Continued revenue growth – Significant pipeline progress

4SC announces financial results for a successful year 2012

4SC to host conference call and webcast on 25 March 2013 to present full year financial results for 2012

ibidi is a Top Winner in the 2012/13 German Economy Innovation Award Competition

4SC AG: Dr Ulrich Dauer to step down as CEO and member of the Management Board on 31 March 2013; his successor will be CFO Enno Spillner

4SC Discovery and LEO Pharma announce exclusive research and license agreement for inflammatory skin diseases

4SC Discovery and BioNTech launch strategic cancer therapy research partnership

Evotec achieves milestone in drug discovery collaboration with Ono Pharmaceutical Co., Ltd.

Evotec and Yale University form Open Innovation Alliance

4SC obtains key patent for anti-cancer compound resminostat in Europe

Evotec expands collaboration with MedImmune, receives milestone payment

Evotec acquires Cell Culture Service GmbH

Evotec and Apeiron Biologics announce collaboration on cancer immunotherapy

2011

Newsletter 06/25

Record financing rounds at the Munich biotech hub

9th Munich Life Science Pitch Day

Life Science Pitch Day at the IZB: Innovations meet Investors

Newsletter 02/24

Christian Gnam succeeds Dr. Peter Zobel as new Managing Director of the Biotechnology Innovation and Start-up Center (IZB)

A year of successes and changes at Munich’s biotech hub

Newsletter 01/24

Newsletter December 2023

Novogene expands its European operations with new genomics facility at the IZB in Munich, Germany

MoleQlar receives seed funding from Rheingau Founders and acquires Munich-based epigenetics specialist EpiQMAx

Newsletter November 2023

Presentation of IZB’s innovation powerhouse in the context of BIO-Europe 2023

Netzwerkveranstaltung BioEurope 2023

GoingPublic.de – Life Sciences 10-23

Dr. Peter Hanns Zobel, CEO of IZB, Bids Farewell

Successful Economic Reception at IZB with Dr. Theo Waigel, Former Federal Minister of Finance, as Guest Speaker

Wirtschaftsempfang / Economic reception 2023

Bind-X secures €10 million in financing as part of its Series B financing round

Biotech Companies from Munich’s start-up center IZB convince prominent partners with excellent research

Viopas Venture Consulting opens office in the Innovation and Start-up Center Biotechnology (IZB)

8th Munich Life Science Pitch Day

Pioneering research projects at the 8th Life Science Pitch Day at the IZB

8th Munich Life Science Pitch Day

Newsletter July 2023

Venture Capital Magazine 05-23

Newsletter May 2023

Innovation and Start-up Center Biotechnology (IZB) welcomes LEON

Tubulis Enters Strategic Partnership with BMS

Newsletter April 2023

16th Biotech Press Lounge

IZBrunch, February 2023

IZBrunch, November 2022

16th Biotech PressLounge

16th Biotech Press-Lounge at the IZB: A new “atlas for human heart cells” may lead to customized and personalized therapies in the future

Plattform Life Sciences 03-23

Newsletter March 2023

Innovation and Start-up Center Biotechnology (IZB) welcomes Invitris

Newsletter February 2023

Successful year for the Munich biotech hub

Venture Capital Magazine 01-23

Innovation and Start-Up Center for Biotechnology (IZB) welcomes T-CURX GmbH

Atriva Therapeutics GmbH moves into the Innovation and Start-Up Center for Biotechnology (IZB)

Plattform Life Sciences 11-22

Plattform Life Sciences 11-22

Venture Capital Magazine 06-22

Venture Capital Magazine 06-22

Süddeutsche Zeitung 2022

Innovation and Start-Up Center for Biotechnology (IZB) welcomes consultancy KLIFO

VC investor Andera Partners opens office in the Innovation and Start-up Center Biotechnology (IZB)

7th Munich Life Science Pitch Day

15th Biotech Press Lounge

Munich Life Science Pitch Day at the IZB: Eleven teams presented to 28 life science investors with an available investment volume of more than 20 billion euros

7th Munich Life Science Pitch Day

15th Biotech PressLounge

15th IZB Biotech Press Lounge: The cocktail for medical progress

Plattform Life Sciences 09-22

IZBrunch vom 21. Juli 2022

Cutting-edge research at Munich’s IZB attracts strong interest

IZBrunch June 30, 2022

Wirtschaftsempfang / Economic reception 2022

Business reception at the Biotechnology Innovation and Start-up Center (IZB) above the roofs of the campus

Plattform Life Sciences 05-22

Tubulis closes a series B financing in the amount of 60 million and moves into IZB in June 2022

Interview Dr. Zobel, münchenTV

14th Biotech Press Lounge

14th Biotech Press Lounge

14th Biotech Press Lounge of the IZB: Medical innovations that are changing the world

Venture Capital Magazine 03-22

Plattform Life Sciences 03-22

Innovation and Start-Up Center for Biotechnology (IZB) welcomes new start-up Origin.Bio

Süddeutsche Zeitung 2022

Münchner Merkur 01-22

dpa 01-22

Munich’s Biotech Valley IZB is Booming

SCG Cell Therapy expands global R&D by opening a research innovation site at the IZB in Germany

PreOmics receives Euro 13.5 million from Bruker Corporation in Series B financing round

IZBrunch, October 21, 2021

Eisbach Bio receives 6.7 million Euros grant from the Bavarian Government

mk2 Biotechnolgies new start-up at the Innovation and Start-up Center Biotechnology (IZB) in Martinsried, near Munich, Germany

IZBrunch, September 23, 2021

6th Munich Life Science Pitch Day

Innovative drug developers presented to over 20 investors at the Munich Start-Up Center

6th Munich Life Science Pitch Day

COVID-19: Start-up Eisbach Bio at the IZB receives EUR 8 million government grant

30.09.2021: Life Science Pitch Day in cooperation with High-Tech Gründerfonds, Bayer AG, Boehringer Ingelheim and IZB

Biotech start-ups at the IZB close deals worth more than 140 million EUR in the first half of 2021

AMSilk receives financing of 29 million euros

Lindis entwickelt Immuntherapie gegen Blasenkrebs

Lindis Biotech develops immunotherapy against bladder cancer

CHEManager 2021

Münchner Merkur 2021

Origenis founds biotech company Neuron23 in Silicon Valley together with star investor Kleiner Perkins

ChromoTek and Absolute Antibody Collaborate on Recombinant Engineered Antibodies

A higher omega-3 level apparently protects from dying from COVID-19

World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools

Innovation network Proteomics4Future explores new technologies for the industrialization of MS-based proteomics

Proteintech uand Chromo Tek, 2020

Handelsblatt, 2020